Metricure is a veterinary medicine used in situations involving certain distressing symptoms in cows, particularly those involving supportive relief to help address specific uterine symptoms. The active ingredient is commonly used to help with subacute and chronic endometritis, a relevant area where short-term symptom management is appropriate.

---

Supports Management of Uterine Symptom Clusters

This medicine helps address symptom clusters that may become intense or disruptive, often related to inflammatory or irritative states within the uterus. It is applied when these groups of symptoms create noticeable functional strain or interfere with the cow's daily comfort and stability. It is used in scenarios involving conditions such as subacute endometritis and chronic endometritis.

---

Offers Assistance in Symptom Stabilization

Metricure is commonly used during phases when symptoms become more noticeable and supportive relief is needed. It offers symptomatic relief that helps patients cope more steadily with difficult episodes, assisting with maintaining a sense of stability when heightened discomfort is present. It may assist with supporting general well-being during symptomatic phases.

“Offers symptomatic relief that helps patients cope more steadily with difficult episodes.”

---

Applicable for Fluctuating Reproductive Conditions

This product is commonly used across conditions characterized by periods of heightened symptoms in the reproductive tract, such as recurrent or episodic manifestations of endometritis. It is considered relevant for easing the overall symptom load when conditions produce significant symptomatic burden.

Quick Fact: May assist with symptoms related to Noticeable Functional Strain

Eligibility Scope

The regulatory profile for Metricure defines strict boundaries for its use. It is authorized only for cows diagnosed with subacute or chronic endometritis, and specifically for animals that are at least 14 days after parturition (calving). The medicine can be used during lactation.

---

Absolute Contraindications

Metricure must not be used in animals with a known hypersensitivity to cephalosporins or other beta-lactam antibiotics, such as penicillin. Regulatory documents classify this as an absolute contraindication.

---

Use Restrictions and Limitations

The product is not indicated for use during pregnancy. Eligibility is also limited by the need to avoid combining treatments: the medicine must not be administered concurrently with other intra-uterine antibiotic preparations. For appropriate use, regulatory documents require that the decision be informed by susceptibility testing of the bacteria causing the infection to confirm its appropriateness.

Interactions with other medicines and products

Interaction Scope

The official regulatory documentation for Metricure (Cefapirin intrauterine suspension) specifies interaction patterns primarily related to the localized administration route. Since systemic absorption of the active ingredient is minimal following intrauterine administration, the regulatory label documents no systemic pharmacokinetic interactions, such as those involving drug-metabolizing enzymes like the CYP450 system, or interactions with food, alcohol, or herbal products.

Interaction Classifications and Restrictions

Classification	Interacting Product Category	Official Regulatory Statement
Prohibited Co-administration	Other Intrauterine Antibiotic Preparations	Must not be administered concurrently with any other intrauterine antibiotic preparations.
Required Sequential Use	Prostaglandins	Prior administration of prostaglandins is recommended in cases of pyometra to help facilitate the removal of uterine debris before Metricure treatment.

The most significant restriction documented in the regulatory label is the explicit prohibition against co-administering Metricure simultaneously with other intrauterine antibiotic preparations. This constraint is a formal, interaction-related restriction. The requirement for sequential use of Prostaglandins establishes a timing-based condition for administration in specific disease contexts.

Irreversible Inhibition of Bacterial Cell Wall Assembly

The active molecule, Cefapirin, is a highly specific covalent inhibitor of Penicillin-Binding Proteins (PBPs), which are bacterial enzymes vital for synthesizing the rigid peptidoglycan layer of the cell wall. By binding permanently to the PBPs, Cefapirin blocks the final cross-linking step necessary for structural integrity. This molecular blockade rapidly triggers osmotic lysis and death of the bacterial cell (bactericidal action), which results in the reduction of the bacterial pathogen load at the site of administration.

⏳ Mechanism Sustained by Local Delivery

The drug is delivered in a specialized, insoluble benzathine salt and oily suspension formulation, which acts as a local reservoir. This system controls the slow dissolution of the active drug, ensuring a prolonged period where Cefapirin's concentration remains above the necessary threshold (Minimum Inhibitory Concentration). This sustained local exposure maximizes the principle of time-dependent killing, supporting the continuous elimination of active bacteria for a persistent biological effect.

Instruction Map: How to use Metricure

Metricure is an intrauterine suspension delivered via a specialized veterinary procedure, with usage parameters defined to facilitate administration.

Entity	Instruction
Route of Administration	Strictly intrauterine use, involving direct infusion into the uterine lumen.
Dosing Schedule	A single, fixed dose delivering 500 mg Cefapirin (as the benzathine salt) is used per treatment.
Preparation Requirements	The syringe must be shaken thoroughly immediately before use to ensure the oily suspension is homogeneous for delivery.
Timing Constraints	Administration is restricted to the post-parturition period, for use no earlier than 14 days after calving.

The medicine is a single-administration course, though a repeat dose may be administered 7 to 14 days later if a clinical assessment determines insufficient resolution. This scheduling establishes the treatment as a short-term intervention. Administration requires the use of the disposable catheter provided with the product. Furthermore, the product is not indicated for use in pregnant animals, focusing its use profile on the non-pregnant, post-calving cow.

Connection to the overall use protocol: The established framework defines a localized delivery structure for the 500 mg dose, where the medicine is administered directly to the target tissue within a specific post-calving timeframe.

Research evidence / Overview of studies for Metricure

Evidence for Use in Subacute and Chronic Endometritis

Research into Metricure has primarily focused on its use in cows diagnosed with subacute or chronic endometritis, which are conditions involving inflammatory or irritative states within the uterus. Research includes Randomized Controlled Trials (RCTs) and supporting systematic reviews that have studied Cefapirin in cows diagnosed with subacute or chronic endometritis, focusing on the primary functional outcomes measured. These trials were used in research exploring how symptoms change over time and were applied in research contexts involving fluctuating or unstable symptoms.

Research examined outcomes related to functional reproductive measures. Researchers monitored the cows for several months to assess their subsequent fertility, including the probability of becoming pregnant after being bred and the time interval between calving and conception. Findings describe patterns observed in these functional outcomes over time. However, research does not determine whether an individual cow will respond similarly. The evidence contributes to the broader evidence landscape and highlights how physiological strain or stress was monitored during the study period.

The existence of multiple RCTs corresponds to an Evidence Level of High for this research area. Despite this, some uncertainty remains. Variability in diagnostic criteria was used across different studies to define endometritis, meaning the populations studied were not always uniform. Furthermore, long-term effects are not fully established; while functional measures were tracked for several months, limited information for long-term outcomes exists regarding the durability of the reproductive patterns beyond the initial conception.

---

Studies for Purulent Vaginal Discharge (PVD) and Related Conditions

Metricure was studied for use in cows presenting with Purulent Vaginal Discharge (PVD), which are outcomes linked to inflammatory or irritative states often associated with the endometritis condition. These trials were typically structured as Randomized Controlled Trials and applied in research contexts involving fluctuating or unstable symptoms.

Studies monitored symptomatic measures, reporting how symptoms evolved in the observed populations, and also included tracking of functional reproductive outcomes. Because PVD is often investigated concurrently as a clinical sign of endometritis, dedicated research focusing solely on PVD is limited. Results apply only to the populations studied, and comparative evidence is lacking for certain PVD-specific treatments.

---

Long-Term Follow-up and Durability of Study Outcomes

Clinical research typically includes intermediate-to-long-term follow-up to track functional reproductive measures, such as time to pregnancy. Studies monitored the initial clinical response at short intervals, with the key reproductive outcomes monitored over subsequent months. This research highlights what is known regarding the functional outcomes measured in the trials. However, the existing studies provide limited information for long-term outcomes beyond the period required to confirm conception.

---

Research in Specific or Limited Populations

Metricure was studied for use in certain specific groups, such as cows categorized as "repeat breeders" (animals that fail to conceive after three or more inseminations). Research examined these populations, which are conditions marked by functional limitations, and was conducted during periods of increased symptom activity. In the case of repeat breeder cases, evidence quality varies across studies, and some subgroup findings are uncertain. The sample sizes were modest, and data for certain groups remain insufficient.

---

Current Evidence Gaps and Areas of Uncertainty

Research provides context but not individual predictions, and findings highlight what is known and what is still uncertain. The primary limitation involves the variability in diagnostic criteria used to define the studied conditions. Further uncertainty exists because comparative evidence is lacking for some of the related conditions. Long-term effects are not fully established, and data for certain specific physiological groups remain insufficient.

Key Studies & References Metricure Summary of Product Characteristics (SPC) - Veterinary Medicines Directorate (VMD)

Common questions about Metricure (FAQ)

---

Q: Is Metricure a type of antibiotic?

Yes. Official documents describe Metricure's active ingredient, Cefapirin, as a first-generation cephalosporin antibiotic.

This classification indicates the medicine has a strong bactericidal action, meaning it is designed to directly kill susceptible bacteria causing the infection.

---

Q: Why do some people refer to Metricure as a 'broad-spectrum' medicine?

The official product classification identifies Metricure's active ingredient, Cefapirin, as a first-generation cephalosporin antibiotic.

This classification establishes the type of bacteria the medicine is effective against, which is defined in the regulatory documentation.

---

Q: If I am allergic to similar drugs, could I also be allergic to Metricure?

Regulatory documents state that the medicine must not be administered to animals with a known allergy to cephalosporin or penicillin antibiotics.

This constraint acknowledges the potential for cross-sensitivity that exists between these two classes of drugs.

---

Q: Is Metricure approved for use in children?

Metricure is strictly classified as a veterinary medicine and is indicated exclusively for use in cows (bovines).

Its regulatory classification specifies the target species as cows (bovines), and it is not intended for human use.

---

Q: Why is it important to complete the full course of Metricure?

The specialized formulation is designed for slow, sustained local release of the active ingredient directly at the infection site.

This system is designed to maximize the principle of time-dependent killing, which regulatory documents describe as supporting the continuous presence of the active ingredient at the site of administration.

---

Q: What is the official safety rating or classification for Metricure?

Metricure is classified as a Prescription Only Medicine (POM-V) by regulatory bodies.

Its single documented adverse reaction (hypersensitivity) is classified as 'very rare,' meaning it is observed in less than 1 animal per 10,000 treated.

---

Q: Does Metricure cause photosensitivity or increased sensitivity to the sun?

The official safety documentation lists only a 'very rare' hypersensitivity reaction as a documented adverse effect.

Other potential side effects, such as increased sun sensitivity or photosensitivity, are not documented in the official adverse reaction list.

---

Q: What is the expected treatment duration for Metricure?

Official guidelines classify Metricure as a single-administration course delivered via an intrauterine procedure.

If insufficient resolution is determined following a clinical assessment, a repeat dose may be administered 7 to 14 days later.

---

Q: Is Metricure considered safe for use in older adults?

Metricure is strictly classified as a veterinary medicine and is indicated exclusively for use in cows (bovines).

Its regulatory classification specifies the target species as cows (bovines), and it is not intended for human use.

---

Q: What is the primary way Metricure is processed by the body?

Following intrauterine administration, regulatory documents confirm that systemic absorption of the active ingredient into the bloodstream is minimal.

This is due to the unique local delivery formulation, which minimizes drug distribution throughout the body.

---

Q: Are there long-term side effects associated with Metricure use?

Research documents indicate that while reproductive function measures were tracked for several months after use, data is limited regarding long-term outcomes.

Specifically, information on the durability of reproductive patterns beyond the initial conception period is limited.

---

Q: What kind of research has been done on Metricure's effectiveness?

Research supporting the product includes Randomized Controlled Trials (RCTs) and systematic reviews.

These studies primarily focused on functional reproductive measures in cows diagnosed with subacute or chronic endometritis.

---

Q: Where can I find the official prescribing information for Metricure?

Official prescribing information is found in regulatory documents such as the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC) and the UK's Veterinary Medicines Directorate (VMD) SPC.

The NOAH Compendium also carries relevant product details.

---

Q: Why might a patient switch from another drug to Metricure?

Official documents highlight the specialized oil-based formulation.

This formulation facilitates the extended local release of the active ingredient directly at the infection site, which is a differentiating characteristic of the product.

---

Q: What do regulatory documents indicate about Metricure and systemic conditions (like kidney function)?

Regulatory documents confirm that systemic absorption of the active ingredient is minimal following intrauterine administration.

This minimal systemic absorption is relevant to how the body processes the medicine.

---

Q: Can I crush or split Metricure tablets, or must they be swallowed whole?

Metricure is not a tablet or a capsule; it is an oily intrauterine suspension.

It is administered directly into the uterine lumen via a specialized catheter and is not intended for oral use, crushing, or splitting.

---

Q: Does Metricure interact with common pain relievers like ibuprofen?

The official regulatory label documents no systemic pharmacokinetic interactions with food, alcohol, or other medicines, including common pain relievers.

This is because absorption into the bloodstream is minimal following intrauterine administration.

---

Q: Can Metricure be taken with hot or cold beverages?

Metricure is an oily intrauterine suspension for direct delivery into the uterus.

Since it is not an oral medicine, it is not taken with hot or cold beverages.

---

Q: Are there any known differences in how Metricure affects men versus women?

Metricure is classified as a veterinary medicine indicated exclusively for use in cows (bovines).

Its use is specific to female reproductive conditions in the target species.

---

Q: What does the latest research say about Metricure's long-term outcome data?

Current research provides limited information for long-term outcomes regarding the durability of reproductive patterns beyond the period required to confirm conception.

Follow-up was conducted for several months, but the full long-term evidence is not fully established.

---

Q: Can Metricure be used by people with diabetes?

Metricure is strictly classified as a veterinary medicine and is indicated exclusively for use in cows (bovines).

Its regulatory classification specifies the target species as cows (bovines), and it is not intended for human use.

---

Q: What is Metricure's effect on the liver or kidney functions?

Regulatory documents confirm that systemic absorption of the active ingredient is minimal following intrauterine administration.

This is why no systemic pharmacokinetic interactions related to organ clearance are documented.

---

Q: What are the common misunderstandings patients have about Metricure's purpose?

The medicine is a veterinary product, specifically an intrauterine suspension for cows.

This key fact about the target species and the localized route of administration is a common point of confusion regarding its intended purpose and use.

How to Store and Dispose of Metricure

Metricure (Cefapirin) must be stored under specific environmental conditions to maintain its stability, as required by regulatory labeling.

---

Storage Conditions

The product must not be stored above 25 C and should be kept in its original outer carton to protect it from light. It must not be frozen or refrigerated. Metricure is a single-use preparation; do not use the product after the stated expiry date. The medicine must be stored out of the sight and reach of children.

Disposal

Disposal of unused or expired Metricure must be done in accordance with local requirements. The product must not be disposed of via wastewater or household waste. Utilize designated take-back schemes or national collection systems for proper pharmaceutical waste disposal.